Pioneer Announces Purchase of CryptoPunk 8869
4.11.2021 21:00:00 EET | Business Wire | Press release
Pioneer Media Holdings Inc. (“Pioneer” or the “Company”) purchased CryptoPunk 8869.
https://www.larvalabs.com/cryptopunks/details/8869
Accessories:
- blue bandana
- muttonchops
- regular shades.
"We are excited about Web3" said Mike Edwards, CEO of Pioneer. "The real question is how do you dive in? We looked for guidance from the community. Answer = Step 1 is buy a JPEG!"
Transaction Details
Pioneer acquired CryptoPunk 8869 for 100.25 ETH (US$ 433,703.58).
The Company provides the following update on what it sees trending in this space.
Web3 is otherwise referred to as the ownership economy because the token economic models reward participation and creativity. NFTs in particular enable coordination around the shared ownership of art and beyond; an investment in this space is more about joining a community than investing in a traditional company and this is why Pioneer decided to acquire a piece of the most iconic collection to date, the CryptoPunk.
NFTs have captured the spirit of the private markets. In the past month, SoRare (private) and Dapper Labs (private) have raised US$680M at a US$4.3B valuation and US$250M at a US$7.6B valuation respectively. In addition, Axie Infinity maker Sky Mavis (private) and Animoca (private) respectively raised US$152M at a US$3B valuation and US$65M at a US$2.2B valuation. Cumulatively that implies +US$1B in fresh capital at a combined market cap of +US$17B for four NFT privates in under a month. NFT sales in Q3 hit US$10.7B up from US$1.3B in Q2 and from US$28M in the same quarter of 2020
While meme stocks have captured the spirit of the public markets. In 2021 ‘Meme stocks’ like GameStop and AMC were completely changed fueled by retail investor euphoria driven by Reddit memes. GameStop raised ~US$1.1 billion after surging +1,200% and AMC raised ~US$1.2 billion driven by the share price appreciation through Reddit memes.
CryptoPunks are one of the primary NFT status symbols in crypto. A CryptoPunk owner refused a US$9.5 million bid for his asset in October, a four year old CryptoPunk 1422 was just sold for US$2 million, and recently a half a billion dollar transaction enabled by a flash loan for Punk 9998
8869, a Punk, a NFT, and a meme stock: Pioneer combines the meme stock and NFT element by becoming the first publicly tradable company to embody a CryptoPunk and allow for fractionalized equity ownership of that CryptoPunk. Through equity ownership in Pioneer, investors will become fractional owners of Punk 8869, a public markets first.
The Pioneer Plan
- Pioneer will be the first true listed Web3 investment company focused on NFT gaming and assets. Building off of its success in mobile gaming (LEAF), eSports (GILD/Dynasty/Paidia) and its foundational investment in NFT Investments.
- Pioneer will invest and acquire the best brands, teams and assets in the space.
About Pioneer Media Holdings Inc.
Pioneer is the first publicly traded issuer that actively invests in a diversified portfolio of early-stage to mid-level companies in Web3 including NFTs and NFT gaming, together with investments in esports, and mobile gaming. Pioneer’s management team leverages its global network to democratize access to investments not normally available to the retail investor community.
The current Pioneer portfolio includes investments such as: Leaf Mobile Inc. (TSX: LEAF), a leading free-to-play mobile games group; Guild eSports plc (LON: GILD), a global eSports business headquartered in London whose lead investor is David Beckham; Dynasty eSports Pte Ltd, creators of the world’s leading white-label Gaming Ecosystem Management solution, partnering exclusively on a B2B basis with Tier 1 telco's and large media organisations; NFT Investments plc, a London based investment company focused on non-fungible tokens (“NFTs”), and Kodoku Studios Ltd., London based team that stands at the forefront of the exciting new NFT gaming genre Pioneer provides capital, experience, and support to these emerging market leaders while building shareholder value. Additional information about Pioneer is available at www.sedar.com.
ON BEHALF OF PIONEER MEDIA HOLDINGS INC.
“Mike Edwards”
CEO & Director
Neither the Canadian Securities Exchange nor any Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Statements
Forward Looking Statements
This news release may contain “forward-looking” statements and information relating to the Company, the funds to be raised, and the use of any such funds that are raised, that are based on the beliefs of Company management, as well as assumptions made by and information currently available to Company management. There is no assurance the Company will be able to complete the placement on the terms as outlined above, or at all. The Company does not undertake to update forward‐looking statements or forward‐looking information, except as required by law.
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211104006125/en/
Contact information
Mike Edwards
Via Tancredi
+44 203 434 2330
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
